Noble Financial Analysts Boost Earnings Estimates for CRDF

Cardiff Oncology, Inc. (NASDAQ:CRDF) – Research analysts at Noble Financial boosted their Q1 2026 earnings per share estimates for Cardiff Oncology in a research report issued on Thursday, March 26th. Noble Financial analyst R. Leboyer now anticipates that the company will earn ($0.14) per share for the quarter, up from their prior estimate of ($0.19). Noble Financial currently has a “Outperform” rating and a $12.00 target price on the stock. The consensus estimate for Cardiff Oncology’s current full-year earnings is ($0.99) per share. Noble Financial also issued estimates for Cardiff Oncology’s Q2 2026 earnings at ($0.15) EPS, Q3 2026 earnings at ($0.17) EPS, Q4 2026 earnings at ($0.18) EPS and FY2026 earnings at ($0.64) EPS.

Cardiff Oncology (NASDAQ:CRDF) last released its earnings results on Tuesday, February 24th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.07. Cardiff Oncology had a negative return on equity of 82.01% and a negative net margin of 7,733.22%.The firm had revenue of $0.24 million during the quarter, compared to analyst estimates of $0.13 million.

A number of other research firms have also weighed in on CRDF. HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Cardiff Oncology in a research note on Wednesday, January 28th. Wall Street Zen upgraded shares of Cardiff Oncology from a “sell” rating to a “hold” rating in a report on Wednesday, March 4th. Piper Sandler dropped their price objective on shares of Cardiff Oncology from $10.00 to $6.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 25th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Cardiff Oncology in a report on Wednesday, January 21st. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $10.10.

Cardiff Oncology Price Performance

CRDF stock opened at $1.55 on Monday. The business’s 50-day moving average is $1.89 and its two-hundred day moving average is $2.20. The firm has a market capitalization of $105.96 million, a P/E ratio of -2.25 and a beta of 1.32. Cardiff Oncology has a 1 year low of $1.48 and a 1 year high of $4.56.

Institutional Trading of Cardiff Oncology

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Jeppson Wealth Management LLC purchased a new stake in shares of Cardiff Oncology during the 3rd quarter worth approximately $25,000. Brooklyn Investment Group purchased a new position in shares of Cardiff Oncology in the 3rd quarter valued at $26,000. Capital Advisors Wealth Management LLC purchased a new position in shares of Cardiff Oncology in the 4th quarter valued at $30,000. Tamar Securities LLC acquired a new stake in Cardiff Oncology during the 4th quarter worth $32,000. Finally, R Squared Ltd acquired a new stake in Cardiff Oncology during the 4th quarter worth $36,000. Institutional investors and hedge funds own 16.29% of the company’s stock.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.